%0 Journal Article %J J Alzheimers Dis %D 2018 %T 11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset. %A Wu, Liyong %A Liu, Jia %A Feng, Xueyan %A Dong, Jing %A Qin, Wei %A Liu, Yang %A Wang, Jingjuan %A Lu, Jie %A Chen, Kewei %A Wang, Yuping %A Jia, Jianping %K Adult %K Biomarkers %K Brain %K Carbon Radioisotopes %K Female %K Frontotemporal Dementia %K Heterozygote %K Humans %K Male %K Middle Aged %K Mutation %K Parkinsonian Disorders %K Pedigree %K Positron-Emission Tomography %K tau Proteins %X

Frontotemporal dementia with parkinsonism-linked to chromosome 17 (FTDP-17) is a rare autosomal dominant neurodegenerative disorder. Most patients with FTDP-17 carry the mutation in the microtubule-associated protein tau (MAPT) gene. Striatum is predominantly and early affected in FTDP-17. Five family members (two symptomatic patients and three presymptomatic mutation carriers) from a Chinese pedigree of FTDP-17 with N279K mutation in MAPT were enrolled. Parkinsonism was the initial symptom for symptomatic patients. 2b-carbomethoxy-3b-(4-trimethylstannylphenyl) tropane (11C-CFT) uptake was obviously affected in the putamen of two presymptomatic mutation carriers. Presymptomatic case 3, whose 11C-CFT uptake in the right putamen was normal at baseline, was still free of parkinsonism during follow-up. In conclusion, 11C-CFT-positron emission tomography could be a potential biomarker for the presymptomatic stage of FTDP-17 to predict the disease onset.

%B J Alzheimers Dis %V 61 %P 613-618 %8 2018 %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/29226866?dopt=Abstract %R 10.3233/JAD-170561